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ABSTRACT
Increasing detection of small renal masses by imaging techniques entails the need for accurate
discrimination between benign and malignant renal cell tumors (RCTs) as well as among malignant RCTs,
owing to differential risk of progression through metastization. Although histone methylation has been
implicated in renal tumorigenesis, its potential as biomarker for renal cell carcinoma (RCC) progression
remains largely unexplored. Thus, we aimed to characterize the differential expression of histone
methyltransferases (HMTs) and histone demethylases (HDMs) in RCTs to assess their potential as
metastasis biomarkers. We found that SETDB2 and RIOX2 (encoding for an HMT and an HDM, respectively)
expression levels was signiﬁcantly altered in RCTs; these genes were further selected for validation by
quantitative RT-PCR in 160 RCTs. Moreover, SETDB2, RIOX2, and three genes encoding for enzymes
involved in histone methylation (NO66, SETD3, and SMYD2), previously reported by our group, were
quantiﬁed (RT-PCR) in an independent series of 62 clear cell renal cell carcinoma (ccRCC) to assess its
potential role in ccRCC metastasis development. Additional validation was performed using TCGA dataset.
SETDB2 and RIOX2 transcripts were overexpressed in RCTs compared to renal normal tissues (RNTs) and in
oncocytomas vs. RCCs, with ccRCC and papillary renal cell carcinoma (pRCC) displaying the lowest levels.
Low SETDB2 expression levels and higher stage independently predicted shorter disease-free survival. In
our 62 ccRCC cohort, signiﬁcantly higher RIOX2, but not SETDB2, expression levels were depicted in cases
that developed metastasis during follow-up. These ﬁndings were not apparent in TCGA dataset. We
concluded that SETDB2 and RIOX2 might be involved in renal tumorigenesis and RCC progression,
especially in metastatic spread. Moreover, SETDB2 expression levels might independently discriminate
among RCC subgroups with distinct outcome, whereas higher RIOX2 transcript levels might identify ccRCC
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Introduction
Kidney cancer incidence is increasing worldwide, with 62,700
new cases and 14,240 deaths estimated for 2016.1 Increasing
incidence has been attributed to the rising number of incidental
small renal tumors diagnosed due to widespread use of imaging
techniques, as well as to aging, obesity, and smoking, which are
known risk factors for the development of kidney cancer.2
Increased detection of small renal masses emphasizes the need
for accurate discrimination not only between benign and
malignant RCTs, but also among malignant RCTs subtypes.
Indeed, renal cell carcinomas (RCCs) that are more likely to
behave aggressively and to develop metastases should be clearly
distinguished from those that will probably have a more indo-
lent growth and might be managed more conservatively.3,4
Among RCCs, the most frequent are clear cell renal cell carci-
noma (ccRCC), papillary renal cell carcinoma (pRCC), and
chromophobe renal cell carcinoma (chRCC). Whereas ccRCC
is the histotype that more frequently develops metastases,
pRCC is more frequently multifocal and chRCC is mostly an
indolent cancer that rarely develops metastases, although its
differential diagnosis with oncocytoma, a benign tumor, might
be challenging.5
Metastasis is the foremost cause of cancer-related mortality,
despite improvements in diagnosis, surgical techniques, patient
care, and adjuvant therapies. Biologic heterogeneity of tumor
cells, as well as differences in metastatic tumor microenviron-
ment at different sites may inﬂuence response to therapy.6
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Thus, understanding pathogenesis of metastases at cellular
and molecular level has become a major goal in cancer
research.6,7 Indeed, management of metastatic renal cell car-
cinoma (mRCC) remains a major clinical challenge. Although
median survival of patients with mRCC has been increasing
due to therapeutic advances, speciﬁcally in antiangiogenic
drugs and tyrosine-kinase inhibitors (from approximately 12
months with cytokine therapy to more than 26 months with
VEGF inhibitors therapy),8 5-year survival for advanced kid-
ney cancer was only 11.7% in the period 2007–2013.9 Albeit
the proportion of patients with mRCC at diagnosis has
declined, due to improved imaging techniques as well as
more intense screening and incidental case ascertainment, a
sizeable number of small RCCs (<4 cm diameter) may pres-
ent renal capsule invasion, tumor thrombus, or lymphatic
and distant metastasis,3,4 and their identiﬁcation constitutes a
major challenge.
Altered epigenetic homeostasis has been implicated in
tumorigenesis and epigenetic-based biomarkers and may
assist in diagnosis, prognostication, and prediction of
response to targeted therapy.10 Histone modiﬁcations and
chromatin modulators, in particular, have been shown to
play an important role in cancer progression.11 In RCC, cer-
tain histone modiﬁcations associate with progression-free
survival and correlate with pathological characteristics of
tumors.12 In addition, defects in epigenetic enzymes,
involved in chromatin remodeling and packaging, have been
implicated in development of RCTs, reﬂecting the role of
these mechanisms in renal tumorigenesis.13 Herein, we aimed
to investigate the potential of HMTs and HDMs expression
as biomarkers of metastatic progression in RCC, using two
independent RCT cohorts, complemented with external vali-
dation in TCGA dataset. We selected SETDB2 (an HMT) and
RIOX2 (an HDM), based on an extended characterization of
histone methyltransferases in RCTs, previously reported by
our group.14 Additionally, we also tested SMYD2 and SETD3
(both HMT), as well as NO66 (HDM), previously evaluated
in our ﬁrst RCT cohort and TCGA dataset,14 in the second
cohort comprising ccRCC with indolent (non-metastatic)
and aggressive (metastatic) disease.
Results
Validation of RIOX2 and SETDB2 expression in RCTs
RIOX2 and SETDB2 expression levels were assessed by quan-
titative RT-PCR in a series of 160 RCTs and 13 RNTs. The
results were fully concordant with those of the TaqMan
Array as both genes were signiﬁcantly overexpressed in RCTs
compared to RNTs (P value <0.0001 for SETDB2 and <0.05
for RIOX2; (Fig. 1A and B). Moreover, RIOX2 and SETDB2
expression levels differed signiﬁcantly between benign and
malignant RCTs (Fig. 1C and D), and among the four RCT
subtypes (Table 1). Oncocytomas displayed the highest
SETDB2 and RIOX2 expression levels, followed by chRCC
(Fig. 1E and F and Table 1). Pairwise comparisons demon-
strated that SETDB2 and RIOX2 expression levels signiﬁ-
cantly differed between chRCC and both pRCC and ccRCC,
and between pRCC and both chRCC and oncocytoma.
Furthermore, SETDB2 transcript levels differed signiﬁcantly
between chRCCs and oncocytomas (Fig. 1E and F and
Table 1).
SETDB2 and RIOX2 expression levels
and clinicopathological correlates
No signiﬁcant differences in gender and age were apparent
between patients and controls. In RCCs, no statistically sig-
niﬁcant associations were disclosed between SETDB2 and
RIOX2 expression levels and Fuhrman or pathological stage
categories. In RCTs, expression levels of both genes were
signiﬁcantly higher in females. Moreover, RIOX2 expression
levels signiﬁcantly associated with patient’s age (P value D
0.015). In ccRCCs and pRCCs, SETDB2 expression levels
were signiﬁcantly lower in patients that developed metasta-
ses (Fig. 2A and B).
SETDB2 and RIOX2 expression levels as prognostic
markers
The median follow-up of RCC patients was 175 months
(range: 2–375 months). A total of 15 patients died from
RCC during this period. In univariable analysis, higher
pathological stage (pT3 or higher) associated with shorter
survival, whereas gender, age, histological subtype, and
Fuhrman grade did not disclose any prognostic value within
the available follow-up time. Disease-speciﬁc survival (DSS)
analysis showed that low SETDB2 and RIOX2 levels were
signiﬁcantly associated with worse outcome (P value <0.01
and <0.05, respectively; (Fig. 3A and B). Concerning
disease-free survival (DFS) analysis, low SETDB2 levels
signiﬁcantly associated with shorter time to disease progres-
sion (P value <0.0001; Fig. 3C). The same trend was
observed for RIOX2, but statistical signiﬁcance was not
reached (P value D 0.055; Fig. 3D).
In this series, only one case with local recurrence presented
distant metastasis before local recurrence developed, thus DFS
is equivalent to metastasis-free survival in this case. In multi-
variable analysis, a ﬁnal model including SETDB2 expression
levels and pathological stage was predictive of disease-free sur-
vival. Indeed, higher risk of disease progression was depicted
for patients with higher pathological stage [HR: 3.03 (1.16-
7.80), P value D 0.024] and lower SETDB2 expression levels
[HR: 5.11 (1.72-15.24), P value D 0.003].
RIOX2, SETDB2, SETD3, SMYD2, and NO66 expression
and risk of metastization in ccRCC
No signiﬁcant differences were apparent for gender (P value D
0.570) and age (P value D 0.402) between ccRCCs patients that
developed metastases and those that did not (cohort #2). Fur-
thermore, no statistically signiﬁcant associations were disclosed
between SETDB2 and RIOX2 expression levels and Fuhrman
grade or pathological stage in this cohort. In this cohort,
expression levels of SETD3, SMYD2, and NO66, which we have
previously found to associate with shorter disease-speciﬁc and
disease-free survival,14 did not signiﬁcantly differ between the
two groups of ccRCC patients (Fig. 4C and E). Concerning
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RIOX2 and SETDB2 expression levels, only the former differed
signiﬁcantly between metastasized and non-metastasized
ccRCCs (Fig. 4B).
RIOX2 and SETDB2 expression in RCC Patients from TCGA
Dataset
In TCGA dataset, signiﬁcantly lower RIOX2 expression levels
were found in RCC compared to RNT, contrarily to our results.
Nevertheless, among RCCs, pairwise comparisons showed that
RIOX2 expression levels were signiﬁcantly higher in chRCCs
compared to ccRCCs and pRCCs, paralleling our ﬁndings. In
ccRCCs from TCGA database, no statistically signiﬁcant differ-
ence was disclosed for RIOX2 expression levels between the
group of patients that developed metastases and those that did
not.
Concerning SETDB2, lower expression levels were depicted
in RCC compared to RNT, as well. In line with our results,
however, pairwise comparisons demonstrated that SETDB2
expression levels were signiﬁcantly higher in chRCCs compared
to ccRCCs and pRCCs, and expression levels signiﬁcantly dif-
fered among subtypes. Considering only ccRCCs from TCGA
database, no statistically signiﬁcant difference was apparent for
SETDB2 expression levels between the group of patients that
developed metastases and those that did not, paralleling our
results.
Discussion
Due to the widespread use of imaging tests, the frequency
of incidentally detected RCTs has signiﬁcantly increased,
consisting mainly of small and early stage tumors. How-
ever, as lymph node and distant metastases may occur even
in small RCCs,15 and the latter constitute the main cause
RCC-related mortality,16 there is an unmet need for bio-
markers capable of accurately discriminate tumors that will
metastasize from those that will not, especially among pT1,
which are the most amenable to nephron-sparing surgery.
Because epigenetic-based biomarkers may assist in diagno-
sis, prognostication and prediction of response to targeted
therapy,10 we hypothesized that histone modiﬁcations and
chromatin modulators11 might aid in the identiﬁcation of
RCCs more prone to recur and metastasize. Indeed, previ-
ous reports have shown that, in RCC, histone modiﬁcations
are associated with pathological features and DFS,12 and
defects in chromatin remodelers and chromatin packaging
are implicated in RCT development.13
In this study, we focused mostly on RIOX2 and SETDB2
expression levels as candidate biomarkers for RCC prognos-
tication. Whereas RIOX2 encodes for an HDM, displaying
high transcript or protein levels in RCC and several other
cancers, associating with poor prognosis,17–24 SETDB2 enco-
des for an HMT involved in leukemogenesis,15 but was not
previously associated with solid tumors. These two genes
were selected based on previously published array data
Figure 1. Expression levels of SETDB2 and RIOX2 in cohort #1. A: SETDB2 expression in renal cell tumors (RCTs) and renal normal tissues (RNTs). B: RIOX2 expression in renal
cell tumors (RCTs) and renal normal tissues (RNTs). C: SETDB2 expression in benign tumors (oncocytoma) and malignant tumors [renal cell carcinoma (RCCs)].
D: RIOX2 expression in benign tumors (oncocytoma) and malignant tumors (renal cell carcinoma (RCCs)]. E: SETDB2 expression in renal cell tumors subtypes. F: RIOX2
expression in renal cell tumors subtypes. (P values: <0.0001; <0.01; <0.05).
Table 1. Comparison of SETDB2 and RIOX2 expression among renal normal tissue
(RNT), renal cell tumors (RCT), renal cell carcinoma (RCC), and RCT histotypes. For
histotype pairwise comparison, the values were statistically signiﬁcant when P
value<0.0125 (Bonferroni’s correction).
SETDB2 (P value) RIOX2 (P value)
RNT vs. RCT <0.001 <0.05
RNT vs. RCC 0.001 0.444
Oncocytoma vs. RCC <0.001 <0.001
ccRCC vs. pRCC 0.392 0.658
ccRCC vs. chRCC <0.001 <0.001
ccRCC vs. oncocytoma <0.001 <0.001
pRCC vs. chRCC <0.001 <0.001
pRCC vs. oncocytoma <0.001 <0.001
chRCC vs. oncocytoma <0.001 0.131
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from our team,14 which were conﬁrmed through analysis of
cohort #1 tissue samples. Indeed, both RIOX 2 and SETDB2
were found overexpressed in RCTs compared to non-paired
normal renal tissues, suggesting that their deregulation is
associated with neoplastic transformation of renal parenchy-
mal cells. Interestingly, renal oncocytomas displayed the
highest RIOX2 and SETDB2 expression levels, signiﬁcantly
differing from RCCs. This result might be of practical value
for distinction between oncocytoma and chRCC, especially
the eosinophilic variant, as both histotypes display variable
degree of morphological overlap, rendering differential diag-
nosis problematic, particularly in small core biopsies.25
Figure 2. Expression levels of SETDB2 (A) and RIOX2 (B) in clear cell renal cell carcinomas and papillary renal cell carcinomas (cohort #1) with or without metastasis
(P value<0.05).
Figure 3. Kaplan-Meier estimated disease-speciﬁc survival curves and disease-free survival curves for SETDB2 (respectively A and C) and RIOX2 (respectively B and D).
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Unexpectedly, when TCGA dataset was interrogated for
RIOX2 and SETDB2 expression in renal tissues, RCCs displayed
signiﬁcantly lower expression levels than normal renal tissues,
contrarily to our ﬁndings in cohort #1. Nonetheless, the expres-
sion ranking among RCCs in TCGA paralleled our ﬁndings,
with chRCC displaying the highest expression levels, compared
to ccRCC and pRCC. This discrepancy might be related with
the origin of the “normal renal tissue” analyzed. Indeed,
whereas in our study RNT samples derived from kidneys not
harboring RCC, those of TCGA dataset were collected from
macroscopically normal looking areas of organs involved in
RCC. As we have previously shown, these “paired” normal
renal tissue samples disclose signiﬁcant epigenetic alterations
that may precede neoplastic transformation.26 Thus, the results
from cohort #1 and TCGA dataset analysis may not be directly
comparable.
A major goal of this study was to ascertain the prognostic
value of RIOX2 and SETDB2 expression levels in RCCs.
Whereas, in univariable analysis, lower RIOX2 and SETDB2
expression levels associated with worse DSS, only lower
SETDB2 levels associated with worse DFS. Interestingly, among
standard clinicopathological parameters, only stage reached
statistical signiﬁcance. In multivariable analysis, however, only
low SETDB2 expression and stage retained statistical signiﬁ-
cance, suggesting that assessment of SETDB2 expression might
add relevant prognostic information for the management of
RCC patients. Although a previous report has associated higher
RIOX2 immunoexpression with shorter DSS in RCC,17 these
results are not directly comparable with ours as we did not
assess protein expression and the proportion of RCC subtypes
also differed. Indeed, in our series, survival analysis results were
mostly inﬂuenced by ccRCC and pRCC, which displayed the
lowest expression levels among RCCs. Moreover, RIOX2 over-
expression has been associated with worse prognosis in esoph-
ageal cancer24 but with favorable outcome in lung cancer,27
emphasizing that the biological and clinical impact of RIOX2
expression is strongly dependent on the primary location and
the speciﬁc cancer type.
Because DFS was analogous to metastasis-free survival in
cohort #1, we looked for differences in SETDB2 expression lev-
els among tumors with and without metastasis. Interestingly,
we found signiﬁcantly lower SETDB2 expression in ccRCC and
pRCC (the more clinically aggressive histotypes) with metasta-
sis. However, when we attempted to validate these ﬁndings is
an independent cohort comprising ccRCC with and without
metastasis (cohort #2) and in ccRCCs from TCGA dataset, no
signiﬁcant differences were disclosed. Nonetheless, signiﬁcantly
higher RIOX2 transcript levels were depicted in ccRCC that
developed metastasis during follow-up compared to matched
ccRCC without metastasis, suggesting that RIOX2 expression
might be a biomarker of progression (metastization) in ccRCC.
Interestingly, high RIOX2 expression levels have been associ-
ated with development of lymphatic or distant metastasis in
bile duct, gastric and pancreatic carcinomas.22,23,28 In TCGA
dataset, however, no differences in RIOX2 expression levels
were apparent between ccRCCs that developed metastases and
those that did not. These discrepancies might be due to differ-
ences in follow-up time and enrolment criteria, as we excluded
from analysis cases that presented metastasis at diagnosis and
only analyzed cases in which metastases developed after cura-
tive-intent surgical treatment. Although we further evaluated
three genes encoding for histone modifying enzymes (SMYD2,
SETD3, and NO66) previously shown to be associated with
worse prognosis in RCC14 in cohort #2, their expression levels
did not signiﬁcantly differ between ccRCC with and without
metastasis.
Although our ﬁndings might be limited by the sample size, it
should be emphasized that the most frequent histotypes are
represented, whereas in many studies only ccRCC cases have
been included. Moreover, survival analysis is based on long-
term follow-up data, including two patient cohorts and TCGA
dataset. Finally, although candidate biomarkers were previously
Figure 4. Expression levels of SETDB2 (A), RIOX2 (B), SETD3 (C), SMYD2 (D), and NO66 (E) in clear cell renal cell carcinomas (cohort #2) with or without metastasis (P value
<0.05).
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identiﬁed in array-based analysis, validation in independent
patient’s series was undertaken, whereas several previous stud-
ies proposing array-based biomarkers for RCC, have not vali-
dated them or have just performed validation in limited series
of patients,29–32 precluding the assessment of its clinical
usefulness.
In conclusion, our results suggest that SETDB2 and RIOX2
might be involved in renal tumorigenesis and RCC progression,
especially in metastatic spread. Moreover, SETDB2 expression
levels might independently discriminate among RCC patient
subgroups with distinct outcome, whereas higher RIOX2 tran-
script levels might identify ccRCC cases with more propensity
to endure metastatic dissemination.
Materials and Methods
Patients and sample collection
A series of 160 RCTs (cohort #1) comprising 40 cases of each
subtype (ccRCC, pRCC, chRCC, and oncocytoma) was pro-
spectively collected from patients consecutively diagnosed and
submitted to nephrectomy at the Portuguese Oncology Insti-
tute of Porto (IPO Porto). As controls, 13 renal normal tissue
(RNT) samples were procured from patients submitted to
nephro-ureterectomy due to upper urinary tract urothelial car-
cinoma, not involving the renal parenchyma. All tissues were
immediately frozen and stored at ¡80C. Sampling of more
than 70% of malignant cells was conﬁrmed using two slides
stained with hematoxylin and eosin (H&E) taken before and
after frozen section collection for RNA extraction. Relevant
clinical data was retrieved from clinical charts.
An independent series of 62 ccRCCc (cohort #2) comprising
31 ccRCCs that have developed metastasis and 31 ccRCCs that
did not progress, matched for gender, age, tumor size, grade,
and stage at diagnosis were also retrieved from the archives.
Tissue samples were prepared as described above.
This study was approved by the ethics committee of IPO
Porto (CES-IPOPFG-EPE 518/10).
RNA extraction
For RNA extraction, samples were suspended in TRIzol
reagent (InvitrogenTM, Carlsbad, CA, USA; Cat. #15596018)
and chloroform (Merck Millipore, Darmstadt, Germany; Cat.
#MCX10601) was added after the cells were lysed. RNA con-
centrations and purity ratios were determined using a Nano-
Drop ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). Samples were then stored at ¡80c.
HMT and HDM selection
Selection of candidate HMTs and HDMs was based on the
results of previously reported custom made TaqMan Array
96-Well expression plates (Applied Biosystems, Foster City,
CA, USA; Cat. #4391528).14 SMYD2, SETD3, and NO66 had
been previously validated and found to be associated with
shorter disease-speciﬁc and disease-free survival.14 Addition-
ally, SETDB2 and RIOX2 expression also displayed high fold
variation between RCTs and RCCs, as well as between chRCC
and oncocytomas, and were thus selected for further validation.
Both presented higher expression in RCT compared to RNT, as
well as in oncocytomas than in chRCC.
Validation of selected enzymes
RIOX2 and SEDTB2 mRNA expression levels were ﬁrstly evalu-
ated in cohort #1. Subsequently, RIOX2, SETDB2, SMYD2,
NO66, and SETD3 expression was assessed in cohort #2.
For validation in cohort #1, 300 ng of mRNA was reverse
transcribed and ampliﬁed using TransPlexWhole Transcrip-
tome Ampliﬁcation Kit (Sigma-Aldrich, St. Louis, MO, USA)
with subsequent puriﬁcation using QIAquick PCR Puriﬁcation
Kit (QIAGEN, Germany), according to manufacturer’s instruc-
tions. RIOX2 and SETDB2 mRNA levels were evaluated using
TaqMan Gene Expression Assays [Applied Biosystems, Fos-
ter City, CA, USA; Hs99999908 m1 (GUSb), Hs99999901 s1
(18S), Hs01126272 m1 (SETDB2), Hs00262155 m1 (RIOX2)]
according to manufacturer’s instructions. For each sample,
expression levels were normalized using two internal reference
gene, GUSb and 18S, according to the formula: target gene rela-
tive expression D target gene expression level / ((GUSb expres-
sion level C 18S expression level) / 2). Each plate included
multiple non-template controls and serial dilutions of a cDNA
Human Reference Total RNA (Agilent Technologies, La Jolla,
CA, USA; Cat. #750500) to construct a standard curve.
For validation in cohort #2, 1 mg of total RNA was reverse
transcribed using the High Capacity cDNA Reverse Transcrip-
tion kit according to the manufacturer’s instructions. RIOX2,
SETDB2, SMYD2, NO66, and SETD3 mRNA levels were evalu-
ated using TaqMan Gene Expression Assays [Applied Bio-
systems, Foster City, CA, USA; Cat. #4331182 Hs00220210
m1 (SMYD2), Hs00260120 m1 (SETD3), Hs02743012 s1
(NO66), Hs99999908 m1 (GUSb), Hs99999901 s1 (18S),
Hs01126272 m1 (SETDB2), Hs00262155 m1 (RIOX2)] accord-
ing to manufacturer’s instructions. For each sample, expression
levels were normalized using two internal reference gene,
GUSb and 18S, according to the formula: target gene relative
expression D target gene expression level / ((GUSb expression
level C 18S expression level) / 2). Each plate included multiple
non-template controls and serial dilutions of a cDNA Human
Reference Total RNA (Agilent Technologies, La Jolla, CA,
USA; Cat. #750500) in order to construct a standard curve.
TCGA dataset analysis in pRCC, chRCC, and ccRCCs
patients
The Cancer Genome Atlas (TCGA) dataset was interrogated for
data on RIOX2 and SETDB2 expression and clinical informa-
tion, when available, from ccRCCs, pRCCs, and ccRCCs
patients. All expression data from samples hybridized at the
University of North Carolina, Lineberger Comprehensive Can-
cer Center, using Illumina HiSeq 2000 RNA Sequencing version
2 analysis, were downloaded from TCGA data matrix (http://
tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp). This dataset
included 533 ccRCC, 290 pRCC, and 66 chRCC. The provided
value was pre-processed and normalized according to “level 3”
speciﬁcations of TCGA (see http://cancergenome.nih.gov/data
portal/ for details). Biospecimen Core Resources (BCRs)
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provided the clinical data of each patient. This data is available
for download through TCGA data matrix (http://tcga-data.nci.
nih.gov/tcga/dataAccesMatrix.htm).
Statistical analysis
Non-parametric tests were used to ascertain statistical signiﬁ-
cance of comparisons among groups. Kruskal-Wallis test (KW)
was used for comparisons among multiple groups and Mann-
Whitney U test (MW) was used for pairwise comparisons. The
prognostic signiﬁcance of clinicopathological variables (age,
gender, histological subtype, pathological stage, Fuhrman
grade) and HMTs and HDMs expression levels was assessed by
constructing disease-speciﬁc and disease-free survival curves
using the Kaplan-Meier method with log-rank test (univariable
test). The expression levels of SETDB2 and RIOX2 were classi-
ﬁed as low or high based on the cutoff value of 25th percentile
for SETDB2 expression and 75th percentile for RIOX2. A Cox-
regression model comprising the different variables (multivari-
able test) was also constructed. For this analysis, the 120 RCC
patients from cohort #1 were included.
Statistical signiﬁcance was set at P value <0.05. Bonferroni
correction was applied for pairwise comparisons following
multiple groups’ analyses. Statistical analysis was performed
using SPSS software for Windows, version 22.0 (IBM-SPSS
Inc., Chicago, IL, USA), and graphs were built using GraphPad
Prism 6.0 software for Windows (GraphPad Software Inc., La
Jolla, CA, USA).
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